HIV Infection

No HIV acquisitions occurred among 315 cisgender and transgender women receiving long-acting cabotegravir PrEP in the real-world US OPERA Cohort, despite mostly short injection delays.

August 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a...

A randomized trial evaluated whether the 4CMenB vaccine prevents gonorrhea among adults at high risk for infection.

A US prescription claims study evaluated uptake and 2-year persistence among users of long-acting injectable cabotegravir for HIV PrEP.

In a multicenter dose de-escalation and expansion study of adults with HIV-related DLBCL, ibrutinib plus R-da-EPOCH showed manageable toxicity and clinical activity, with 3-year event-free and overall...

Improving TDF-FTC uptake among US young men who have sex with men on HIV PrEP could yield substantial 10-year value, while a hypothetical study eliminating adverse event uncertainty would not change the...

A phase 3 trial found that switching from bictegravir–emtricitabine–tenofovir alafenamide to once-daily bictegravir–lenacapavir maintained viral suppression in adults with HIV-1.

The FDA approved a once-daily, 2-drug oral regimen for adults with virologically suppressed HIV-1 to replace existing antiretroviral therapy.

A large national database study presented at CROI 2026 in Denver, CO, reports that 5-year survival remains lower for people with HIV compared with people without HIV across most treatment modalities for...

In a phase 3b trial, monthly dapivirine ring and daily oral PrEP were assessed for safety, adherence, and acceptability in pregnancy.